• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=15153938).
  

PubMed=10741907; DOI=10.1007/s004320050023
Wu Q., Kreienberg R., Runnebaum I.B.
Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro.
J. Cancer Res. Clin. Oncol. 126:139-144(2000)

PubMed=11242531; DOI=10.1089/10430340150504019
Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J., Kreienberg R., Runnebaum I.B.
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001)

PubMed=15153938; DOI=10.1038/sj.cgt.7700727
Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Cancer Gene Ther. 11:547-554(2004)